ShareHope Medicine Co Ltd (8403) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of ShareHope Medicine Co Ltd TWD 21.22, price TWD 18.95, upside +12.0%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ShareHope Medicine Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
ShareHope Medicine Co., Ltd. provides integrated medical services in Taiwan. The company is involved in health management and operation activities; human resource dispatch of professional medical staff services.
Show more
ShareHope Medicine Co., Ltd. provides integrated medical services in Taiwan. The company is involved in health management and operation activities; human resource dispatch of professional medical staff services. It also offers provision of medical, pharmaceutical, and health devices, as well as long-distance health care services; and rental of medical devices. ShareHope Medicine Co., Ltd. was founded in 2003 and is based in Taoyuan City, Taiwan.
Stock analysis
ShareHope Medicine Co Ltd (8403) currently trades at 18.95 TWD, while our model-based Fair Value estimate is 21.22 TWD, implying the stock looks roughly 10.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 23.52 TWD per share, and 14 of the 23 models we run sit above the 18.95 TWD price.
Bear case: the Earnings-Based group reads lowest at 10.89 TWD, and 9 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: 17.16 TWD (bear) to 26.64 TWD (bull), the price of 18.95 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
ShareHope Medicine Co Ltd reported revenue of 4.4B TWD in FY2025 versus 3.9B TWD in FY2021, a compound +3.1%/yr. Reported net income was 142M TWD in FY2025, compounding −11.7%/yr from FY2021.
Key figures
Market cap 2.6B TWD (≈ $82.1M) · P/E ratio 16.1 · P/S ratio 0.52 · EPS (TTM) 1.18 TWD · Net margin 3.3% · Return on equity 2.7% · Return on assets (EBIT) 3.4% · Operating margin 1.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at 12%, 8403 screens richer than that median.
Fair Value models
Bear 17.16 TWDFair Value 21.22 TWDBull 26.64 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.8664 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 4%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +1.1% a year for the price.
Compare ShareHope Medicine Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+12% · Above median
Profitability
Return on equity (TTM)3% · Below median
Return on assets1% · Below median
Net margin (TTM)3% · Above median
Operating margin (TTM)2% · Below median
Growth and dividend
Revenue growth2% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "ShareHope Medicine Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8403
Frequently asked questions
Is ShareHope Medicine Co Ltd (8403) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 21.22 TWD versus a price of 18.95 TWD, about +12% upside (undervalued).
What is the fair value of 8403?
Our model-based fair value for ShareHope Medicine Co Ltd is 21.22 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 18.95 TWD.
What is the quality score of 8403?
ShareHope Medicine Co Ltd has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ShareHope Medicine Co Ltd (8403)?
Our model-based price target is the fair value of 21.22 TWD (as of Sep 24, 2026) from 23 valuation models. Cautious scenario 17.16 TWD, optimistic scenario 26.64 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the ShareHope Medicine Co Ltd stock forecast for 2026?
Our models put fair value at 21.22 TWD, about +12% upside versus a price of 18.95 TWD (undervalued). Cautious scenario 17.16 TWD, optimistic scenario 26.64 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of ShareHope Medicine Co Ltd (8403)?
ShareHope Medicine Co Ltd reported trailing-twelve-month revenue of about 4.4B TWD (latest available figure, as of Sep 24, 2026).
What growth is priced into ShareHope Medicine Co Ltd (8403)?
For today's price to be fair in a discounted-cash-flow model, ShareHope Medicine Co Ltd would have to grow free cash flow by +2.7 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 8403 use?
Our models discount ShareHope Medicine Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.16, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ShareHope Medicine Co Ltd that is +2.7 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has ShareHope Medicine Co Ltd (8403) delivered so far?
Over the past 5 years revenue at ShareHope Medicine Co Ltd grew +1.2 % a year. The price currently implies +2.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ShareHope Medicine Co Ltd (8403) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into ShareHope Medicine Co Ltd (+2.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ShareHope Medicine Co Ltd (8403)?
The free-cash-flow yield on the price is 8.91 %: that much free cash flow ShareHope Medicine Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ShareHope Medicine Co Ltd (8403)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ShareHope Medicine Co Ltd it is 21.22 TWD per share (as of Sep 24, 2026), against a price of 18.95 TWD. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is ShareHope Medicine Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 8403 trades below its calculated fair value: price 18.95 TWD, fair value 21.22 TWD, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8403?
No. The price is what the market pays today (18.95 TWD); the fair value is what the company's own numbers justify (21.22 TWD). For ShareHope Medicine Co Ltd the two are 2.27 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is ShareHope Medicine Co Ltd worth?
The market values ShareHope Medicine Co Ltd at about 2.6B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 18.95 TWD; our models calculate a fair value of 21.22 TWD per share.
What do the bullish and bearish scenarios say about 8403?
Our models span a range for ShareHope Medicine Co Ltd: cautious scenario 17.16 TWD, base 21.22 TWD, optimistic 26.64 TWD per share (as of Sep 24, 2026, price 18.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 8403?
ShareHope Medicine Co Ltd trades at a price-to-earnings ratio of 16.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.22 TWD is built from several models across several years. Other multiples: P/B 0.8, P/S 0.6, EV/EBITDA 6.2.
How solid is the balance sheet of ShareHope Medicine Co Ltd (8403)?
Balance-sheet figures for ShareHope Medicine Co Ltd (as of Sep 24, 2026): return on equity 2.7%, debt of 0.24 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 8403 from its 52-week high?
ShareHope Medicine Co Ltd trades at 18.95 TWD, about 25% below its 52-week high of 25.20 TWD and 2% above the low of 18.61 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 21.22 TWD is for.
Which stocks are comparable to ShareHope Medicine Co Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ShareHope Medicine Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 18.95 TWD, calculated fair value 21.22 TWD (+12%), Quality Score 50/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8403 calculated?
We run ShareHope Medicine Co Ltd through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 21.22 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. ShareHope Medicine Co Ltd currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ShareHope Medicine Co Ltd (8403)?
The closing price on Sep 24, 2026 was 18.95 TWD. Our model-based fair value is 21.22 TWD, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ShareHope Medicine Co Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of ShareHope Medicine Co Ltd
How large is the market capitalisation of ShareHope Medicine Co Ltd (8403)?
The market capitalisation of ShareHope Medicine Co Ltd is 2.6B TWD (≈ $82.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ShareHope Medicine Co Ltd (8403)?
The price-to-sales ratio of ShareHope Medicine Co Ltd is 0.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ShareHope Medicine Co Ltd (8403)?
Earnings per share at ShareHope Medicine Co Ltd are 1.18 TWD (price ÷ EPS = P/E 16.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ShareHope Medicine Co Ltd (8403)?
The net margin of ShareHope Medicine Co Ltd is 3.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ShareHope Medicine Co Ltd (8403)?
The return on equity (ROE) of ShareHope Medicine Co Ltd is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ShareHope Medicine Co Ltd (8403)?
On an EBIT basis the return on assets of ShareHope Medicine Co Ltd is 3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ShareHope Medicine Co Ltd (8403)?
The operating margin of ShareHope Medicine Co Ltd is 1.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ShareHope Medicine Co Ltd (8403)?
Revenue at ShareHope Medicine Co Ltd is growing +2.4% versus a year earlier (3y avg +1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ShareHope Medicine Co Ltd (8403)?
Earnings per share at ShareHope Medicine Co Ltd are growing −42.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ShareHope Medicine Co Ltd (8403) carry?
The net debt of ShareHope Medicine Co Ltd is 58.3M TWD (fiscal year 2024, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ShareHope Medicine Co Ltd in the live analysis
One click puts ShareHope Medicine Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
